Emergent BioSolutions Inc. (EBS)

US — Healthcare Sector
Peers: ZTS  PETQ  BHC  NBIX  AKAN  LFCR  PBH  ITCI  IZQVF  ALKS  CPIX  DCPH  COLL  DRRX 

Automate Your Wheel Strategy on EBS

With Tiblio's Option Bot, you can configure your own wheel strategy including EBS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol EBS
  • Rev/Share 17.6471
  • Book/Share 10.1599
  • PB 0.6142
  • Debt/Equity 1.2045
  • CurrentRatio 6.3164
  • ROIC -0.0871

 

  • MktCap 338693472.0
  • FreeCF/Share 1.7353
  • PFCF 3.5879
  • PE -2.5795
  • Debt/Assets 0.4668
  • DivYield 0
  • ROE -0.2727

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation EBS H.C. Wainwright -- Buy -- $15 Dec. 30, 2024
Initiation EBS Rodman & Renshaw -- Buy -- $16 Aug. 22, 2024

News

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
EBS
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral

GAITHERSBURG, Md., June 05, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) is teaming up with Victoria's Voice Foundation to rally Americans to help save lives from the opioid epidemic on National Naloxone Awareness Day, which honors the late Victoria Siegel and others who have succumbed to overdose. As part of the effort, Victoria's Voice has launched the "Shine. Wear. Share. Care" campaign to raise awareness and provide educational resources to individuals, organizations and businesses that includes a purple light bulb (Shine), a wearable promotional item (Wear), a QR code encouraging participation in the #sharenaloxone social media campaign (Share) …

Read More
image for news Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost
ACDVF, ADNT, BTSG, BYON, EBS
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive

Broker-favored picks like BYON, BTSG, ACDVF, EBS, and ADNT are worth monitoring amid EU tariff delay and rising consumer confidence.

Read More
image for news 5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost
5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes
ACDVF, BTSG, BYON, DINO, EBS
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors would do well to monitor broker-favored stocks like BTSG, BYON, ACDVF, DINO, and EBS for high returns.

Read More
image for news 5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes
Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript
EBS
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral

Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2025 Earnings Call May 7, 2025 5:00 PM ET Company Participants Frank Vargo - Vice President, Assistant Treasurer Joe Papa - President and Chief Executive Officer Rich Lindahl - Executive Vice President and Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by.

Read More
image for news Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
EBS
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Emergent Biosolutions (EBS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.59 per share a year ago.

Read More
image for news Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
EBS
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral

GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025.

Read More
image for news Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
EBS
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global contract research, development, and manufacturing organization, for a total value of $36.5 million. The Bayview site includes manufacturing, laboratory, warehousing and office space, and is fitted with multiple monoclonal antibody (mAbs) manufacturing lines.

Read More
image for news Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
EBS
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2024.

Read More
image for news Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
EBS
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral

Separately, Company leaders will attend and present at J.P. Morgan's 2025 Leveraged Finance Conference on February 24, 2025 Separately, Company leaders will attend and present at J.P. Morgan's 2025 Leveraged Finance Conference on February 24, 2025

Read More
image for news Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

About Emergent BioSolutions Inc. (EBS)

  • IPO Date 2006-11-15
  • Website https://www.emergentbiosolutions.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Mr. Joseph C. Papa Jr., M.B.A., R.Ph.
  • Employees 900

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.